Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer

被引：0

作者：

Shuang Liu

Shoujing Zhao

Yang Dong

Tingting Wang

Xiaojia Niu

Lijing Zhao

Guan Wang

机构：

[1] Jilin University,Key Laboratory for Molecular Enzymology and Engineering, National Engineering Laboratory for AIDS Vaccine, The Ministry of Education, School of Life Sciences

[2] Jilin University,Department of Rehabilitation, School of Nursing

来源：

Cancer Chemotherapy and Pharmacology | 2021年 / 87卷

关键词：

CUDC-907; Antitumor activity; Combination treatment; VS-5584; Pancreatic cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：415 / 423

页数：8

共 50 条

[31] Dual inhibition of HDAC and PI3 kinase signaling pathways with CUDC-907 in treatment of p53-driven medulloblastoma
Ronecker, Jennifer S.
Pazniokas, Julia
Amin, Anubhav G.
Scortegagna de Medeiros, Raphael Salles
Epelman, Sidnei
Ghandi, Chirag
Zanon, Nelci
Schmidt, Meic H.
Jhanwar-Uniyal, Meena
CANCER RESEARCH, 2018, 78 (13)
[32] PHASE 1 TRIAL OF CUDC-907, A NOVEL, ORAL DUAL INHIBITOR OF HDAC AND PI3K: UPDATED ASSESSMENT OF PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE EXPRESSOR LYMPHOMA
Younes, A.
Berdeja, J.
Patel, M.
Kelly, K.
Flinn, I.
Gerecitano, J.
Neelapu, S.
Copeland, A.
Wang, J.
Gong, L.
Clancy, M.
Ma, A.
Sun, K.
Wang, J.
Viner, J.
Oki, Y.
HAEMATOLOGICA, 2016, 101 : 175 - 175
[33] A First-In-Man Phase 1 Study Of CUDC-907, a First-In-Class Chemically-Designed Dual Inhibitor Of PI3K and HDAC In Patients With Refractory Or Relapsed Lymphoma and Multiple Myeloma
Younes, Anas
Flinn, Ian W.
Oki, Yasuhiro
Copland, Amanda
Fattaey, Ali
Lai, Cheng-Jung
Laliberte, Robert
Voi, Maurizio
Berdeja, Jesus G.
BLOOD, 2013, 122 (21) : 4363 - 4365
[34] Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer
Zheng Jian
Yichao Han
Wentian Zhang
Chengqiang Li
Wei Guo
Xijia Feng
Bin Li
Hecheng Li
Cell & Bioscience, 12
[35] Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer
Jian, Zheng
Han, Yichao
Zhang, Wentian
Li, Chengqiang
Guo, Wei
Feng, Xijia
Li, Bin
Li, Hecheng
CELL AND BIOSCIENCE, 2022, 12 (01):
[36] Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases
Kotian, Shweta
Zhang, Lisa
Boufraqech, Myriem
Gaskins, Kelli
Gara, Sudheer Kumar
Quezado, Martha
Nilubol, Naris
Kebebew, Electron
CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5044 - 5054
[37] Development of an HDAC/PI3K dual inhibitor in academia
Saijo, Ken
Ishioka, Chikashi
ANNALS OF ONCOLOGY, 2017, 28 : 49 - 49
[38] Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Younes, Anas
Berdeja, Jesus G.
Patel, Manish R.
Flinn, Ian
Gerecitano, John F.
Neelapu, Sattva S.
Kelly, Kevin R.
Copeland, Amanda R.
Akins, Amy
Clancy, Myles S.
Gong, Lucy
Wang, Jing
Ma, Anna
Viner, Jaye L.
Oki, Yasuhiro
LANCET ONCOLOGY, 2016, 17 (05): : 622 - 631
[39] A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with the Duel PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients with MYC-Altered Disease
Landsburg, Daniel J.
Ramchandren, Radhakrishnan
Lugtenburg, Petronella J.
Kelly, Kevin R.
Younes, Anas
Gharavi, Robert
Tuck, David P.
Barta, Stefan Klaus
BLOOD, 2018, 132
[40] CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression
Fu, Xu-hong
Zhang, Xiong
Yang, Hong
Xu, Xiao-wei
Hu, Zong-long
Yan, Juan
Zheng, Xing-ling
Wei, Rong-rui
Zhang, Zhu-qing
Tang, Shi-rui
Geng, Mei-yu
Huang, Xun
ACTA PHARMACOLOGICA SINICA, 2019, 40 (05) : 677 - 688

← 1 2 3 4 5 →